Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis

Trial Profile

Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Bacterial infections; Bronchiectasis
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPIRE-II
  • Sponsors Bayer
  • Most Recent Events

    • 23 May 2018 Results assessing the impact of Exacerbation Definition in RESPIRE 1 and RESPIRE 2 trials, presented at the 114th International Conference of the American Thoracic Society
    • 01 Jan 2018 Results assessing safety and efficacy published in the European Respiratory Journal
    • 24 May 2017 Primary endpoint (Frequency of exacerbation within a 48-week treatment period) has not been met as per the results presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top